Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor

Positive Phase III data for Tesaro's PARP inhibitor, niraparib, have edged the drug ahead of its pipeline competitors and set the company up to give AstraZeneca's marketed therapy, Lynparza, a run for its money – but will modest PFS results be enough to convince regulators to grant a broader ovarian cancer approval for niraparib?